Research programme: antifungals - DorlinAlternative Names: AJ-V-6D; Antifungals research programme - Dorlin; DP 214; Fatty acid synthase inhibitors research programme - Dorlin; Research programme: fatty acid synthase inhibitors - Dorlin
Latest Information Update: 28 Nov 2002
At a glance
- Originator Dorlin Pharmaceuticals; Nonindustrial source
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Mycoses
Most Recent Events
- 28 Nov 2002 No development reported - Preclinical for Mycoses in USA (unspecified route)
- 12 Oct 2000 Preclinical development for Mycoses in USA (Unknown route)